BIOLARGO, INC. – What You Need to Know

Thinking about investing in BioLargo? It is a fascinating company, but before you put your money on the line, let’s look at the latest updates. Think of this as your plain-English guide to what is happening under the hood.

1. What does this company actually do?

BioLargo acts as a science incubator and engineering firm. They develop new technologies and try to make money by licensing them or selling products directly.

• Odor & Air Quality: Their main product, CupriDyne Clean, is a non-toxic deodorizer used in waste management and pet care.
• Water Treatment: Their "AEC" system uses electricity to remove "forever chemicals" (PFAS) from water with a 99% success rate.
• Energy: They are building Cellinity™, a liquid battery for large-scale energy storage.
• Medical & Engineering: Their subsidiary provides engineering consulting. They also develop wound-care products like Stalwart.

2. The "Pooph" Problem & Revenue Risks

BioLargo is in a legal fight with their former largest customer, Pooph Inc., over unpaid bills.

• The Impact: Losing Pooph caused BioLargo’s annual revenue to drop 56% in 2025. This shows a major risk: the company relies too heavily on a few customers.
• The Reality Check: BioLargo lacks long-term, guaranteed contracts. Their revenue is unpredictable because it relies on individual orders. If they cannot replace the lost Pooph sales, they may struggle to pay for daily operations, research, and legal fees.

3. The "Fragile" Financials & Stock Risks

BioLargo is in a tough financial spot. Their auditors have warned that the company might not be able to stay in business without raising more money.

• The "Credit Card": They have an agreement to sell up to $10 million of their own stock to Clearthink Capital Partners to fund operations.
• The Dilution Trap: Because the company loses money, they sell new shares to pay bills. This creates more shares, which reduces your ownership percentage and the value of your existing shares.
• The "Penny Stock" Hurdle: The stock trades on the OTCQB market. Because it is not on a major exchange, it is considered a "penny stock." This can make it harder to buy or sell shares and may lead to higher trading costs.
• Internal Controls: Management admits their systems for tracking and reporting financial data are not effective. This increases the risk of accounting errors.

4. Growing Pains & Real-World Hurdles

• No Dividends: The company has never paid a dividend and does not plan to. You only make money if the stock price rises.
• Patent Risks: BioLargo has limited cash to defend its patents. If a competitor steals their ideas, BioLargo may not have the money to sue them.
• David vs. Goliath: In the energy sector, they compete against giants like Tesla, who have much larger budgets.
• Disaster Risk: Their operations are in Southern California. A major earthquake or wildfire could cripple them, and they lack the insurance to cover a total loss.

5. The Bottom Line

BioLargo is a high-risk, speculative company. They are fighting to survive, hampered by weak financial controls and a need to constantly sell more stock to pay the bills.

This is a gamble on a company still trying to prove its business model works. If you are considering an investment, ask yourself: Am I comfortable with the high probability that this company may need to dilute my shares further or face significant liquidity issues in the near future? Only invest money you are 100% comfortable losing.

Disclaimer: I am an AI, not a financial advisor. This guide is for informational purposes only. Always do your own research or consult with a licensed professional before investing.